<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35672483</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-1741</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature reviews. Immunology</Title><ISOAbbreviation>Nat Rev Immunol</ISOAbbreviation></Journal><ArticleTitle>COVID-19 and Down syndrome: the spark in the fuel.</ArticleTitle><Pagination><StartPage>404</StartPage><EndPage>405</EndPage><MedlinePgn>404-405</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41577-022-00745-w</ELocationID><Abstract><AbstractText>In individuals with Down syndrome, immune dysregulation is partially caused by chromosome 21 trisomy. Here, we discuss how these immune differences may result in poorer COVID-19 outcomes, including diminished responses to vaccination and possibly elevated risk for long COVID.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Majithia</LastName><ForeName>Manini</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pathology Advanced Translational Research Unit (PATRU), Department of Pathology &amp; Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribeiro</LastName><ForeName>Susan P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Pathology Advanced Translational Research Unit (PATRU), Department of Pathology &amp; Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, US. susan.pereira.ribeiro@emory.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Immunol</MedlineTA><NlmUniqueID>101124169</NlmUniqueID><ISSNLinking>1474-1733</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="Y">Down Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>7</Day><Hour>23</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35672483</ArticleId><ArticleId IdType="pmc">PMC9171732</ArticleId><ArticleId IdType="doi">10.1038/s41577-022-00745-w</ArticleId><ArticleId IdType="pii">10.1038/s41577-022-00745-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Malle L, et al. Individuals with Down syndrome hospitalized with COVID-19 have more severe disease. Genet. Med. 2021;23:576&#x2013;580. doi: 10.1038/s41436-020-01004-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41436-020-01004-w</ArticleId><ArticleId IdType="pmc">PMC7936948</ArticleId><ArticleId IdType="pubmed">33060835</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong XF, et al. Three copies of four interferon receptor genes underlie a mild type I interferonopathy in Down syndrome. J. Clin. Immunol. 2020;40:807&#x2013;819. doi: 10.1007/s10875-020-00803-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-020-00803-9</ArticleId><ArticleId IdType="pmc">PMC7418179</ArticleId><ArticleId IdType="pubmed">32572726</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumida TS, et al. Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells. Nat. Immunol. 2022;23:632&#x2013;642. doi: 10.1038/s41590-022-01152-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01152-y</ArticleId><ArticleId IdType="pmc">PMC8989655</ArticleId><ArticleId IdType="pubmed">35301508</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari M, et al. Autoimmunity and genetic syndromes: a focus on Down syndrome. Genes (Basel) 2021;12:268. doi: 10.3390/genes12020268.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes12020268</ArticleId><ArticleId IdType="pmc">PMC7918365</ArticleId><ArticleId IdType="pubmed">33668420</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler CGK, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181:1016&#x2013;1035. doi: 10.1016/j.cell.2020.04.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.035</ArticleId><ArticleId IdType="pmc">PMC7252096</ArticleId><ArticleId IdType="pubmed">32413319</ArticleId></ArticleIdList></Reference><Reference><Citation>De Toma I, et al. Network analysis of Down syndrome and SARS-CoV-2 identifies risk and protective factors for COVID-19. Sci. Rep. 2021;11:1930. doi: 10.1038/s41598-021-81451-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-81451-w</ArticleId><ArticleId IdType="pmc">PMC7820501</ArticleId><ArticleId IdType="pubmed">33479353</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentini D, et al. Safety and long-term immunogenicity of BNT162b2 vaccine in individuals with Down syndrome. J. Clin. Med. 2022;11:694. doi: 10.3390/jcm11030694.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11030694</ArticleId><ArticleId IdType="pmc">PMC8836979</ArticleId><ArticleId IdType="pubmed">35160144</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi AY, et al. Immune evaluation and vaccine responses in Down syndrome: evidence of immunodeficiency? Vaccine. 2011;29:5040&#x2013;5046. doi: 10.1016/j.vaccine.2011.04.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.060</ArticleId><ArticleId IdType="pmc">PMC3909669</ArticleId><ArticleId IdType="pubmed">21596078</ArticleId></ArticleIdList></Reference><Reference><Citation>Fourati S, et al. Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination. Nat. Commun. 2016;7:10369. doi: 10.1038/ncomms10369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms10369</ArticleId><ArticleId IdType="pmc">PMC4729923</ArticleId><ArticleId IdType="pubmed">26742691</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group. et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Preprint at. medRxiv. 2022 doi: 10.1101/2022.03.02.22271623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.03.02.22271623</ArticleId><ArticleId IdType="pmc">PMC9333998</ArticleId><ArticleId IdType="pubmed">35908569</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>